We recently compiled a list of the Jim Cramer Recommends These 10 Stocks. In this article, we are going to take a look at where Lineage Inc. (NYSE:LINE) stands against the other stocks recommended by Jim Cramer.
In a recent episode of Squawk on the Street, Jim Cramer discussed how global markets have become more interconnected than ever. He compared this to 1987, when Japan’s influence on U.S. stocks was clear, with Japanese investors driving up prices in sectors like waste management and railroads. This connection between markets was strong then, and it’s even stronger now.
“Obviously, we went down on Japan, and we went up on Japan. This is somewhat reminiscent of 1987, when, if Japan was up, they’d come over and flood our markets. Sometimes they didn’t care; they’d just start buying stocks, often starting with waste management and Browning-Ferris. “
Cramer explained that the weakening dollar further enhances this global link, benefiting companies that sell internationally, such as Coca-Cola. He also observed a significant shift in investor behavior—where people once looked for reasons to stay out of the market, they now seem more inclined to stay in, finding optimism even in bad news. This change in attitude mirrors today’s market environment, where good news lifts stocks, and even bad news is met with hope for a recovery.
“Back in the day, you’d wonder why Browning-Ferris was up, and the answer would be, ‘Large buyer, large buyer, large buyer.’ Eventually, you’d go out for a beer, and it turns out it’s Tokyo. They loved the rails. There was such craziness back then, but now, we’re even more linked. And with the dollar continuing to weaken, it’s good that we’re linked for companies like that.”
Jim Cramer noted the irony of discussing September as a traditionally bad month for the market. He pointed out that when people focus too much on a specific month being negative, it often doesn’t turn out that way. Cramer also mentioned that despite this expectation, the market had been up significantly, making last week’s market behavior seem unusual.
“Well, it’s funny. You talked about September being a bad month last week, so maybe we get there in a roundabout way. I know that when you single out a month, that’s often when it doesn’t happen. But I also know that we’re up big, and last week seemed odd.”
Our Methodology
For this article, we reviewed a recent episode of Jim Cramer’s Squawk on the Street and his post on the key things to watch in the stock market for Monday. We selected ten stocks that he mentioned and included information on hedge fund sentiment for each. The stocks are ranked by the number of hedge funds that own them, from lowest to highest.
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A scientist in a lab conducting research on cell-based therapeutics and biotechnology.
Lineage Inc. (NYSE:LINE)
Number of Hedge Fund Investors: N/A
Jim Cramer highlights that Wall Street analysts are generally positive about Lineage Inc. (NYSE:LINE). According to Cramer, over a dozen firms have begun covering Lineage Inc. (NYSE:LINE), and more than half of these firms have rated the stock as a buy or a buy-equivalent.
“Wall Street analysts are largely upbeat on cold-storage logistics operator Lineage, which went public in late July with the biggest U.S. IPO of the year. By my count, more than a dozen firms have started coverage on Lineage, with more than half rating the stock a buy or buy-equivalent.”
Lineage Inc. (NYSE:LINE), a biotechnology firm focused on regenerative medicine, offers an appealing investment opportunity due to its innovative technologies and promising development pipeline. Lineage Inc. (NYSE:LINE) is advancing lead products like OPC1, a stem cell-based therapy designed for spinal cord injuries, which addresses major medical needs and holds significant market potential.
Its pipeline also features treatments for retinal degenerative diseases and spinal cord injuries, with ongoing and upcoming clinical trials that could attract investor interest if they show positive results. Strategic partnerships with major pharmaceutical companies and research institutions, such as the California Institute for Regenerative Medicine, provide essential funding, resources, and expertise for Lineage Inc. (NYSE:LINE).
Lineage Inc. (NYSE:LINE) has already reached key milestones, including successful clinical trials and progress in its therapeutic programs. Notably, the advancements in OPC1 trials underscore the potential for substantial therapeutic benefits, boosting Lineage Inc. (NYSE:LINE)’s investment appeal.
Overall LINE ranks 10th on our list of the best stocks to buy according to Jim Cramer. While we acknowledge the potential of LINE as an investment, our conviction lies in the belief that under the radar AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LINE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.
